Moleculin Biotech Q1 FY26 net loss widens to $12.85 million; operating loss widens to $7.87 million

• Moleculin Biotech posted a net loss of $12.85 million for the quarter ended March 31, 2026, widening from $5.9 million a year earlier.
• Operating loss widened to $7.87 million as research and development expense rose to $5.38 million, while general and administrative costs were $2.49 million.
• Cash used in operating activities increased to $6.11 million, while net cash provided by financing activities slipped to $7.61 million.
• Phase 2B/3 MIRACLE trial first unblinding remains on track to occur prior to June 30, 2026; preliminary blinded data for first 45 subjects showed CRc exceeding 40% with CR about 30%.
• Cash and cash equivalents, including $0.8 million raised after quarter-end via ATM sales, expected to fund operations into third quarter of 2026; additional funding need of about $25 million cited to support operations into first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017034), on May 14, 2026, and is solely responsible for the information contained therein.